ProCE Banner Activity

HBcrAg: A Novel Serum Biomarker With Potential for HCC Risk Prediction

Clinical Thought
Patients achieving a functional cure for chronic hepatitis B with nucleos(t)ide analogue treatment may still develop HCC. What tools do we have to predict which patients will experience progression of liver disease?

Released: May 06, 2021

Expiration: May 05, 2022

No longer available for credit.

Share

Faculty

Yasuhito Tanaka

Yasuhito Tanaka, MD, PhD

Chief Professor
Department of Gastroenterology and Hepatology
Faculty of Medicine
Kumamoto University
Kumamoto, Japan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Yasuhito Tanaka, MD, PhD

Chief Professor
Department of Gastroenterology and Hepatology
Faculty of Medicine
Kumamoto University
Kumamoto, Japan

Yasuhito Tanaka, MD, PhD, has disclosed that he has received funds for research support from Fujirebio, and fees for non-CME/CE services from Fujirebio and Gilead Sciences.